LONG-TERM SAFETY PROFILE OF THE ORAL SPLEEN TYROSINE KINASE INHIBITOR FOSTAMATINIB IN IMMUNE THROMBOCYTOPENIA (ITP) AND OTHER DISEASES
a Department of Haematology, St James’ University Hospital, Leeds, United Kingdom
b Dept. of Clinical Science, Rigel Pharmaceuticals, Inc., South San Francisco, United States
c Medical Affairs, Rigel Pharmaceuticals, Inc., South San Francisco, United States
d Department of Research, Rigel Pharmaceuticals, Inc., South San Francisco, United States
e Medical Affairs Knight Therapeutics, São Paulo, Brazil
Read
254
Timeswas read the article
147
Total PDF
107
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 May | 18 | 19 | 37 |
| 2024 April | 17 | 10 | 27 |
| 2024 March | 24 | 29 | 53 |
| 2024 February | 13 | 19 | 32 |
| 2024 January | 9 | 9 | 18 |
| 2023 December | 9 | 23 | 32 |
| 2023 November | 13 | 29 | 42 |
| 2023 October | 4 | 9 | 13 |
